Springworks Therapeutics (SWTX) reported a Q4 net loss Thursday of $1.04 per share, narrowing from a net loss of $1.44 a year earlier.
Analysts polled by FactSet expected a loss of $0.71.
Net product revenue for the quarter ended Dec. 31 was $61.5 million. The previous year's numbers were not provided.
Three analysts surveyed by FactSet expected product revenue of $61.7 million.
The biopharmaceutical company held cash and cash equivalents worth $461.9 million as of Dec. 31. Two analysts polled by FactSet expected $466.8 million.
Shares of the company were up more than 10% in recent premarket activity.
Price: 61.80, Change: +6.07, Percent Change: +10.89
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.